Table 2. Univariate and multivariate cox proportional hazard analysis for prognostic factors of SCLC patients.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (≥60 vs. <60 y) | 1.164 (0.661–2.051) | 0.599 | |||
| Gender (male vs. female) | 1.032 (0.589–1.809) | 0.911 | |||
| Smoking status (present vs. absent) | 0.807 (0.452–1.441) | 0.468 | |||
| Tumor size (≥3 vs. <3 cm) | 0.667 (0.369–1.205) | 0.190 | |||
| Tumor staging (extensive vs. limited) | 7.871 (3.726–16.630) | <0.001 | 0.272 (0.102–0.727) | 0.009 | |
| Lymph node metastasis (present vs. absent) | 8.590 (3.889–18.974) | <0.001 | 0.317 (0.129–0.777) | 0.012 | |
| Brain metastasis (present vs. absent) | 5.675 (2.847–11.313) | <0.001 | 0.428 (0.198–0.925) | 0.031 | |
| PNS (present vs. absent) | 2.315 (1.028–5.214) | 0.043 | 0.495 (0.197–1.243) | 0.134 | |
| NOVA1 expression (low vs. high) | 0.193 (0.100–0.372) | <0.001 | 0.445 (0.213–0.934) | 0.032 | |
SCLC, small cell lung cancer; PNS, paraneoplastic neurological syndromes; NOVA1, neuro-oncological ventral antigen-1; CI, confidence interval.